About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a publicly listed company based in San Diego (United States) founded in 1987. Pharmaceutical drugs are manufactured and developed in the United States. The company has 68 employees. Ligand Pharmaceuticals has completed 16 acquisitions, including Ab Initio, Apeiron Biologics and Crystal Biosciences. Its chief executive, as recorded, is Todd Davis. Ligand Pharmaceuticals offers products and services including Captisol Technology and Royalty Portfolio Management. Its focus areas include Traditional Pharmaceuticals, Generics and Therapeutic Areas. Its legal entity is Ligand Pharmaceuticals Incorporated.
Company details
Ligand Pharmaceuticals was founded in 1987 and is headquartered in San Diego, United States. Operations are centered on the biopharmaceutical sector, where drugs are developed, manufactured, and commercialized for therapeutic applications. The company is led by CEO Todd Davis. Focus is placed on innovative pharmaceutical solutions, with activities conducted primarily in the domestic market. Domain services support ongoing research and production efforts.
- Headquarters San Diego, United States
- Employees 68
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ligand.com
- Social LinkedIn X
- Legal Name Ligand Pharmaceuticals Incorporated
- Annual Revenue$268.09 M (USD)60.4as on Dec 31, 2025
- Net Profit$124.45 M (USD)as on Dec 31, 2025
- EBITDA$80.9 M (USD)33.92as on Dec 31, 2025
- Latest Funding Round$650M (USD), Post-IPO
May 2018
- Employee Count68
- Investments & AcquisitionsAb Initio
& 15 more
Products & Services of Ligand Pharmaceuticals
Ligand Pharmaceuticals offers a comprehensive portfolio of products and services, including Captisol Technology and Royalty Portfolio Management.
This technology is utilized for enhancing drug solubility and stability in development processes
Royalties from biopharmaceutical programs are managed across various disease areas
Funding Insights of Ligand Pharmaceuticals
- Total Rounds 2
- Last Round Post-IPO — $650M
- First Round $245M
(Aug 2014)
All 2 funding rounds of Ligand Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $650M | Post-IPO | – | – | – |
| Aug 2014 | $245M | Post-IPO | – | – | – |
People of Ligand Pharmaceuticals
37 people are tracked at Ligand Pharmaceuticals (21 in leadership, 6 in board & advisors, 10 in team); the tracked headcount is 68.
| Name | Role | Group |
|---|---|---|
Todd Davis | CEO | Leadership |
Bryan W. | Senior Director, Information Services & Facilities | Leadership |
Benjamin Perrone | Sr. Director, Business Development & Licensing | Leadership |
Tavo Espinoza | CFO | Leadership |
Andrew Reardon | Chief Legal Officer | Leadership |
James Pipkin | VP, New Product Development, Captisol | Leadership |
Jessica Wolzen | Associate Director, Regulatory & Operations | Leadership |
Jenny Li | Vice President, Corporate Controller | Leadership |
Ryan Patterson | Associate Director, Financial Reporting | Leadership |
Melanie Herman | Executive Director Investor Relations And Fp&a | Leadership |
Robert Furlani | Assistant General Counsel & Chief Patent Counsel | Leadership |
Lin Zhi | Vice President, Chemistry & Pharmaceutical Sciences | Leadership |
Shetaun T. Deering | Director Of Operations | Leadership |
Paul Hadden | Senior Vice President, Investments And Business Development | Leadership |
Alex Vasilyev | Director, Technical Accounting | Leadership |
Lauren Hay | Vice President, Strategic Planning & Investment Analytics | Leadership |
John M. Gay | Novan Chief Financial Officer | Leadership |
Sima Gupta | Senior Director Tax | Leadership |
Russell Coleman | Director, Strain Engineering | Leadership |
Keith Haney | VP, Operations | Leadership |
17 more people are available in the full profile.
Complete people profiles for Ligand Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ligand Pharmaceuticals
Ligand Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol LGND in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Nov 1992
- Listed onNASDAQ: LGND
- Listed entityLigand Pharmaceuticals Incorporated
- Exchange sectorHealth technology
- ISINUS53220K5048
- Share price$303.53 (-2.44% on the day) · 2026-10-13
- Market capitalisation$6.05B
- Price to earnings32.5
- EPS (diluted, trailing year)$9.35
- Volume (last session)196,563
Financials of Ligand Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $268.1M | $124.5M | $80.9M |
| 2024 | $167.1M | -$4.0M | $60.4M |
| 2023 | $131.3M | $52.1M | $47.2M |
| 2022 | $196.2M | -$33.4M | $56.2M |
| 2021 | $241.5M | $57.1M | $107.6M |
Detailed financial statements for Ligand Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ligand Pharmaceuticals
Ligand Pharmaceuticals has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Ab Initio, Apeiron Biologics and Crystal Biosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-based therapeutics are developed for endocrine and metabolic diseases. | xoma.com | Berkeley, United States | 1981 | Jul 2026 | •••• | |
Tumour-targeting antibodies and immunotherapeutics are developed for cancer treatment. | apeiron-biologics.com | Vienna, Austria | 2005 | Jul 2024 | $100M | |
Novel cow antibodies are developed for therapeutic applications. | taurusbiosci.com | San Diego, United States | 2018 | Sep 2020 | $5M | |
Developer of immuno-oncology antibody therapeutics | xcellabio.com | Menlo Park, United States | 2016 | Sep 2020 | $7M | |
Clinical-stage development of non-glycosylated biosimilar therapeutics | pfenex.com | San Diego, United States | 2009 | Aug 2020 | $516M | |
GPCR-modulating protein agents and immuno-oncology drugs are developed. | aibio.com | San Francisco, United States | 2015 | Jul 2019 | $12M | |
Vernalis is engaged in structure-based drug discovery collaborations. | vernalis.com | Wokingham, United Kingdom | 1999 | Aug 2018 | $42.3M | |
Kidney-safe X-ray contrast agents are developed through US drug reformulation. | verrow.com | Lenexa, United States | 2006 | Jan 2018 | $2M | |
Specialty company developing antibodies | crystalbioscience.com | Emeryville, United States | 2008 | Oct 2017 | $25M | |
Monoclonal antibody technologies are developed for biotech applications. | openmonoclonaltechnology.com | Palo Alto, United States | 2007 | Dec 2015 | $178M |
Complete acquisition details for Ligand Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ligand Pharmaceuticals
14 dated milestones of Ligand Pharmaceuticals across 39 years, from founding to its latest funding, stage changes and deals.
- Founded Ligand Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $245.0M.
- Acquisition Acquires Open Monoclonal Technology.
- Acquisition Acquires Crystal Biosciences.
- Acquisition Acquires Verrow Pharmaceuticals.
- Funding Latest funding round, Post-IPO, of $650.0M.
- Acquisition Acquires Vernalis.
- Acquisition Acquires Ab Initio.
- Acquisition Acquires Pfenex.
- Acquisition Acquires Taurus Biosciences.
- Acquisition Acquires xCella.
- Acquisition Acquires Apeiron Biologics.
- Acquisition Acquires XOMA Corporation.
Web traffic of Ligand Pharmaceuticals
The website of Ligand Pharmaceuticals (ligand.com) receives about 7K visits a month and ranks #3,254,882 among all websites worldwide, #4,274 in Biotechnology and Pharmaceuticals.
- Monthly visits7K
▲ 16.9% vs previous month
- Unique visitors2.6K
per month
- Global rank#3,254,882
among all websites
- Category rank#4,274
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.8
- Average visit33 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Ligand Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pxpharma.com | pxpharma.com | 100% | – | ||
| serono.com | 100% | View details | |||
| ankebio.com | 100% | 1.2K | #1,166,402 | View details | |
| hgsi.com | 100% | View details | |||
aplagen.com | aplagen.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Ligand Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Ligand Pharmaceuticals (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ligand Pharmaceuticals
Complete news archive for Ligand Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ligand Pharmaceuticals
Ligand Pharmaceuticals was founded in 1987 and raised its 1st funding round 27 years after it was founded.
Ligand Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Todd Davis is the CEO of Ligand Pharmaceuticals, as recorded in our data.
Ligand Pharmaceuticals has 68 employees.
Annual revenue of Ligand Pharmaceuticals is $268.09M as on Dec 31, 2025.
Ligand Pharmaceuticals was founded in 1987 and is headquartered in San Diego, United States. Operations are centered on the biopharmaceutical sector, where drugs are developed, manufactured, and commercialized for therapeutic applications. The company is led by CEO Todd Davis. Focus is placed on innovative pharmaceutical solutions, with activities conducted primarily in the domestic market. Domain services support ongoing research and production efforts.
Ligand Pharmaceuticals offers Captisol Technology and Royalty Portfolio Management.
Yes, Ligand Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol LGND.
Ligand Pharmaceuticals has made 16 acquisitions, including Ab Initio, Apeiron Biologics, and Crystal Biosciences.
Ligand Pharmaceuticals operates through Ligand Pharmaceuticals Incorporated.